IgA nephropathy
Coverage of IgA nephropathy in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
The FDA approved Trutakna, a kidney disease drug from Vera Therapeutics, for treating IgA nephropathy at an annual price of $425,000. U.K. officials are finalizing a pricing deal with AstraZeneca and Daiichi Sankyo to provide access to Enhertu, a breast cancer drug previously deemed too costly for the U.K. market.
- Vera Therapeutics stock jumps after the FDA approved its autoimmune kidney drug
Vera Therapeutics' stock increased following FDA approval of Trutakna, a $425,000-per-year drug targeting BAFF and APRIL proteins for IgA nephropathy. The drug is the first in the U.S. to address both proteins linked to the condition.
- First-in-Class Drug Approved for IgA Nephropathy
The FDA granted accelerated approval to atacicept (Trutakna) for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression. Approval was supported by data from the ORIGIN 3 trial for the once-weekly self-administered drug.
- STAT+: FDA approves Vera Therapeutics kidney disease treatment
The FDA approved Trutakna, a new treatment for IgA nephropathy, a chronic autoimmune kidney disease, developed by Vera Therapeutics. Vera CEO Marshall Fordyce expressed excitement about bringing the drug to patients.
- Clinical Trial Helps Young Athlete Return to the Field, Highlighting Research at Locally-Based Kaiser Permanente Southern California
A Southern California college athlete with IgA nephropathy, a chronic kidney disease, returned to baseball after participating in a clinical trial at Kaiser Permanente Southern California. The trial enabled Chance Shipley to resume his senior season following a health decline that forced him to leave the sport.
- STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
Otsuka's Voyxact slowed kidney function loss in IgA nephropathy patients by 3 points annually versus 7.6 points with placebo in a Phase 3 trial, but the effect was less than expected. The drug's performance left room for competing treatments to outperform.
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
A radiopharmaceutical shows promise in the post-Pluvicto setting. Vera Therapeutics and the FDA agreed to accelerate analysis of a Phase 3 study for atacicept in treating IgA nephropathy, while Abivax reported positive data for an ulcerative colitis treatment despite cancer concerns.